JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Thoracic surgical procedures supported by a pumpless interventional lung assist.

BACKGROUND: For support of pulmonary function during complex thoracic surgical procedures, especially in respiratory compromised patients, a pumpless interventional lung assist (iLA) was applied. Feasibility and effectiveness for this novel indication were evaluated.

METHODS: Ten patients underwent thoracic surgery with respiratory support by iLA. Indication for iLA application was the need for intraoperative prolonged discontinuation of ventilation (tracheal surgery and lung resections after pneumonectomy [n = 6], and emergency procedures in patients with acute respiratory failure [n = 4]. The pumpless extracorporeal system was inserted percutaneously into the femoral blood vessels before surgery. Blood flow through the iLA, cardiac output, and gas exchange were monitored.

RESULTS: In all patients, the surgical procedure was successfully performed because of the support by the pumpless iLA. Mean blood flow across the iLA was 1.58 +/- 0.3 L/min (1.2 L/min to 2.2 L/min). Low-dose norepinephrine was required to maintain sufficient systemic blood pressure. There was a moderate improvement in oxygenation (49 mL/min transfer of O(2)) and a very efficient elimination of carbon dioxide (121 mL/min transfer of CO(2)). Thus, extended periods of apneic oxygenation were possible during surgery. The device was removed immediately after surgery in 6 patients. In 4 patients with severe respiratory insufficiency, the iLA was continued for a mean of 6.8 days to allow for protective postoperative ventilation.

CONCLUSIONS: The application of pumpless iLA was hemodynamically well tolerated, and allowed for safe procedures in respiratory compromised patients, avoiding the application and consequences of cardiopulmonary bypass or pump-driven extracorporeal membrane oxygenation.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app